Prosecution Insights
Last updated: April 19, 2026
Application No. 18/026,568

METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS WITH DOUBLE AND TRIPLE COMBINATIONS OF ANTIVIRAL AND IMMUNE MODULATING COMPOUNDS

Final Rejection §DP
Filed
Mar 15, 2023
Examiner
LEWIS, PATRICK T
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Iaterion Inc.
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
2y 6m
To Grant
89%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
844 granted / 1135 resolved
+14.4% vs TC avg
Moderate +14% lift
Without
With
+14.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
40 currently pending
Career history
1175
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
30.5%
-9.5% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
21.4%
-18.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1135 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s Response Dated November 24, 2025 In the Response dated November 24, 2025, claims 66 and 68 were amended, and claims 1-65 were canceled. Claims 66-70 are pending. An action on the merits of claims 66-70 is contained herein. The provisional rejection of claims 66-70 on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 16, and 31-39 of copending Application No. 18/026,567 (reference application) is maintained for the reasons of record as set forth in the Office Action dated August 22, 2025. Rejections Set Forth in the Office Action Dated August 22, 2025 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 66-70 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 16, and 31-39 of copending Application No. 18/026,567 (reference application). No arguments were set forth by applicant. Conclusion Claims 66-70 are pending. Claims 66-70 are rejected. No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Contacts Any inquiry concerning this communication or earlier communications from the examiner should be directed to PATRICK T LEWIS whose telephone number is (571)272-0655. The examiner can normally be reached Monday to Friday, 10 AM to 4 PM EST (Maxi Flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Deirdre Claytor can be reached at (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PATRICK T LEWIS/Primary Examiner, Art Unit 1691 /PL/
Read full office action

Prosecution Timeline

Mar 15, 2023
Application Filed
Aug 20, 2025
Non-Final Rejection — §DP
Nov 24, 2025
Response Filed
Jan 27, 2026
Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599594
Treatment Of Fabry Disease In ERT-Naïve And ERT-Experienced Patients
2y 5m to grant Granted Apr 14, 2026
Patent 12599595
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
2y 5m to grant Granted Apr 14, 2026
Patent 12595281
Indodicarbocyanine Phosphoramidites with Bathochromically Shifted Absorption and Emission, and Tunable Hydrophobicity
2y 5m to grant Granted Apr 07, 2026
Patent 12594292
ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS
2y 5m to grant Granted Apr 07, 2026
Patent 12584124
MAGNETIC BEAD BASED NUCLEIC ACID EXTRACTION SYSTEM
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
89%
With Interview (+14.3%)
2y 6m
Median Time to Grant
Moderate
PTA Risk
Based on 1135 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month